Evidence map›Paper›PMID 40708667›Full record

ArticleRoyal Society open science2025

Modelling immunity gaps to quantify infection resurgences.

Alex James, Reuben McGregor, Natalie Lorenz, Nicole J Moreland, Miguel Moyers-Gonzalez

Abstract read
In one paragraph

Article in Royal Society open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alex JamesUniversity of Canterbury, Christchurch, Canterbury, New Zealand.ORCID https://orcid.org/0000-0002-1543-7139
Reuben McGregorDepartment of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.
Natalie LorenzDepartment of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.
Nicole J MorelandDepartment of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.ORCID https://orcid.org/0000-0001-6548-637X
Miguel Moyers-GonzalezUniversity of Canterbury, Christchurch, Canterbury, New Zealand.ORCID https://orcid.org/0000-0003-4817-1506

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When COVID-19 restrictions were removed, many countries observed infection surges in respiratory pathogens like respiratory syncytial virus (RSV) and influenza. This has been postulated to have been caused by reduced immunity in populations due to non-pharmaceutical interventions that reduced transmission of these pathogens. This pandemic-related phenomenon has been termed 'immunity debt' or 'immunity gap'. We propose a simple extension of the classic susceptible-immune-susceptible model to explore this phenomenon. The model is parametrized using RSV antibody data derived from healthy adults in Aotearoa, New Zealand. We consider a case study based on the prolonged stringent public health measures during the border closure years of 2020-2022 and compare these findings to observed hospitalization trends in Aotearoa, New Zealand. Our model predicts that diseases with very fast waning immunity are less likely to see increased infection rates after prolonged periods of stringent public health measures. However, diseases that wane moderately fast, such as RSV, are more likely to see a strong resurgence of cases when restrictions ease. Our results can be used to predict disease characteristics most likely to lead to strong resurgences after periods of prolonged restrictions and thus inform future public health responses.

Indexed as

disease resurgencemathematical epidemiologypartial differential equation model

Identifiers

PMID40708667
PMCPMC12289187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.